CFRA Research Becomes Exclusive Global Equity Research Provider for Geneva-Based Banque Audi Suisse
5.12.2024 11:00:00 CET | Business Wire | Press release
Exclusive partnership expands access to global equity research for Bank Audi Suisse team of investment professionals through CFRA’s industry-leading MarketScope Advisor Platform.
CFRA, the world’s leading provider of independent investment research today announced that its global fundamental equity, thematic, and sector research is now available to Banque Audi Suisse investment professionals and relationship managers, exclusively through their MarketScope Advisor platform.
The partnership provides Banque Audi Suisse with real-time access to CFRA’s industry-leading research and analytical tools to help their investment teams stay on top of changes in global markets, make well-informed investment decisions, and deliver value to their affluent client base.
"Our search for a global equity research provider was driven by our commitment to delivering maximum value to our client base,” said Hans Itburrun, Head of Investments for Banque Audi Suisse. “It was critical that the partner we chose be able to provide a comprehensive global view of equity markets, had a strong foundation of U.S. coverage, and was backed by a strong track record of performance, CFRA easily checked all those boxes and was able to deliver their research to our team through a turnkey, easy-to-use platform.”
"We are delighted to be selected as the exclusive provider of global equity research to Banque Audi Suisse,” says Patricia Wilson, Chief Solutions Officer for CFRA. “This strategic partnership is an important step in our focus on the Swiss market and underscores the value our research and technology offering for private banks and their clients.”
With decades of experience providing unbiased and actionable research, CFRA’s equity research is trusted globally by more than 150,000 financial advisors and relationship managers through its industry-leading MarketScope Advisor platform.
ABOUT CFRA
A global leader in financial intelligence solutions and insights, CFRA blends a proprietary mix of fundamental equity, forensic accounting, fund, public policy/legal, and technical research with data, analytics, and next-gen technology to arm clients with the financial intelligence required to meet their business and investing goals.
Learn more about CFRA Research and their MarketScope Advisor platform.
ABOUT BANQUE AUDI SUISSE
Banque Audi (Suisse) SA was first established in Zurich in 1976. Its headquarters were later relocated to Geneva, close to the city’s historic Old Town and famous lake. Operating under a Swiss banking license and under the supervision of the Swiss Financial Market Supervisory Authority (FINMA), Banque Audi Suisse offers tailor-made Private Banking services to high-net-worth clients, with access to products and foreign exchange markets all over the world.
In the latest study of November 2024 of Zurich University of Applied sciences (ZHAW) on the Best Private Banks in Switzerland in 2024, Banque Audi Suisse has been ranked as the “Best Capitalized Swiss Private Bank 2024”.
Learn more about Banque Audi Suisse.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241205074954/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom